Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.37 |
| ▸ | CD44 | P16070 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20594973 | 0.82 | KDM4E (0.30) | — | |
| Hydrochloric Acid SCHEMBL29840002 | 0.81 | — | — | |
| SCHEMBL22332534 | 0.76 | DRD2 (0.33) | — | |
| SCHEMBL21507880 | 0.75 | HTR2C (0.35) | PNMTCD44HTR6HTR2C | |
| SCHEMBL17348367 | 0.72 | NOS3 (0.38) | HTR2C | |
| SCHEMBL3800030 | 0.72 | DRD4 (0.37) | HTR2C | |
| SCHEMBL15248113 | 0.72 | PNMT (0.38) | PNMTCD44MAOBHTR2C | |
| SCHEMBL19684580 | 0.72 | PNMT (0.41) | PNMTCD44 | |
| SCHEMBL17590022 | 0.71 | PNMT (0.36) | PNMTCD44HTR6MAOBPOLB | |
| SCHEMBL21507883 | 0.71 | NOS3 (0.36) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | RTF2, REV1, PCNA | PNMT 1195/4885CD44 4778/4885HTR6 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.